Ivabradine Therapy Considerations

Primary Indications and Contraindications

The American College of Cardiology recommends ivabradine for patients with heart failure and reduced ejection fraction, as it reduces the risk of heart failure hospitalization by 26% when added to guideline-directed medical therapy 4
Ivabradine should be considered when heart rate remains elevated (>70 bpm) despite optimal β-blockade in patients with heart failure and reduced ejection fraction 1, 2, 3
The European Society of Cardiology suggests ivabradine is effective for symptomatic treatment of chronic stable angina in patients with heart rate ≥70 bpm who cannot tolerate or whose symptoms are inadequately controlled with β-blockers 5
Ivabradine provides antianginal and anti-ischemic effects similar to other antianginal agents, with benefits seen in the subgroup with chronic stable angina and heart failure 1, 2

In patients with hypotension, ivabradine is preferable to other antianginal agents that lower blood pressure, according to the European Heart Journal 3, 9
Ivabradine is appropriate when elevated heart rate (>70 bpm) is present and requires reduction without affecting blood pressure or contractility, as stated by the American Heart Association 6, 7, 8

Ivabradine is contraindicated in patients with chronic stable angina and atrial fibrillation, as it may increase the incidence of the arrhythmia, warns the American College of Cardiology 1, 2, 3, 9, 6
The drug increases the risk of atrial fibrillation and requires regular cardiac rhythm monitoring; discontinue if atrial fibrillation develops, advises the European Society of Cardiology 1, 2, 3
Combining ivabradine with diltiazem or verapamil is clearly contraindicated, as it may contribute to heart rate lowering, according to the Journal of the American College of Cardiology 9, 6, 7, 8

In adult patients age ≥75 years, consider starting ivabradine at 2.5 mg twice daily, recommends the American Geriatrics Society 4
Ensure patients are in sinus rhythm before initiating therapy; a history of paroxysmal AF is not an absolute contraindication if sinus rhythm is present at least 40% of the time, states the American College of Cardiology 4

Visual symptoms (phosphenes) occur in 5.4% of patients taking ivabradine, are mild and transitory, and only rarely lead to treatment withdrawal (<1%), reports the European Society of Cardiology 5
Bradycardia may increase the risk of QT prolongation, which may lead to severe ventricular arrhythmias, including torsade de pointes, warns the American Heart Association [4